Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Novartis AG (NOVN.SW)
Basel, BS, CH
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.37% | -1.82% | +1.66% | -9.72% | +12.77% | +8.59% | +23.92% | +35.18% | +49.29% | +68.92% | +706.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 5 | 0 |
| Hold | 10 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 0 | -1 |
-
Revenue growth Drug Manufacturers - General: +6.6%+10.5% ★ Q1'26: -5.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+27.6% ★ Q1'26: -11.5% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+27.0% Q1'26: +25.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+32.2% ★ Q1'26: +28.5% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+21.8% ★ Q1'26: +15.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-3.9% ★ Q1'26: -3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×1.54× Q1'26: 2.44× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2001 actual |
Dec 2002 actual |
Dec 2003 actual |
Dec 2004 actual |
Dec 2005 actual |
Dec 2006 actual |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 20 Rev. Ana. 15 EPS Ana. |
Dec 2027 20 Rev. Ana. 15 EPS Ana. |
Dec 2028 17 Rev. Ana. 7 EPS Ana. |
Dec 2029 14 Rev. Ana. 2 EPS Ana. |
Dec 2030 8 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
18.76B
est: 19.07B (-1.6%)
|
20.88B
est: 24.47B (-14.7%)
|
24.93B
est: 24.79B (+0.6%)
|
27.28B
est: 28.95B (-5.8%)
|
29.75B
est: 32.57B (-8.7%)
|
35.11B
est: 37.28B (-5.8%)
|
38.95B
est: 40.34B (-3.5%)
|
42.58B
est: 41.41B (+2.8%)
|
45.10B
est: 44.02B (+2.5%)
|
51.56B
est: 51.51B (+0.1%)
|
59.38B
est: 59.65B (-0.5%)
|
51.97B
est: 57.56B (-9.7%)
|
52.72B
est: 58.91B (-10.5%)
|
53.63B
est: 58.99B (-9.1%)
|
50.39B
est: 50.28B (+0.2%)
|
49.44B
est: 49.60B (-0.3%)
|
43.40B
est: 47.92B (-9.4%)
|
46.10B
est: 51.50B (-10.5%)
|
48.68B
est: 46.48B (+4.7%)
|
49.90B
est: 43.53B (+14.6%)
|
43.97B
est: 47.51B (-7.4%)
|
43.46B
est: 47.61B (-8.7%)
|
46.66B
est: 54.53B (-14.4%)
|
51.72B
est: 50.44B (+2.6%)
|
57.13B
est: 55.45B (+3.0%)
|
55.58B
53.89B – 56.99B
+0.2% YoY
|
59.00B
57.23B – 62.45B
+6.1% YoY
|
62.79B
60.89B – 65.45B
+6.4% YoY
|
65.51B
63.53B – 68.29B
+4.3% YoY
|
68.33B
66.26B – 71.23B
+4.3% YoY
|
| EBITDA |
5.95B
est: 6.04B (-1.6%)
|
7.19B
est: 7.88B (-8.8%)
|
7.26B
est: 7.04B (+3.2%)
|
7.97B
est: 9.80B (-18.7%)
|
8.78B
est: 10.17B (-13.6%)
|
10.18B
est: 11.01B (-7.5%)
|
10.58B
est: 12.11B (-12.6%)
|
12.46B
est: 17.34B (-28.1%)
|
12.77B
est: 13.77B (-7.2%)
|
15.81B
est: 13.99B (+13.1%)
|
17.09B
est: 17.70B (-3.4%)
|
16.53B
est: 15.79B (+4.7%)
|
15.90B
est: 16.37B (-2.9%)
|
17.66B
est: 15.47B (+14.1%)
|
14.36B
est: 15.34B (-6.4%)
|
14.57B
est: 22.96B (-36.6%)
|
14.59B
est: 13.60B (+7.3%)
|
20.24B
est: 15.36B (+31.8%)
|
15.62B
est: 17.53B (-10.9%)
|
17.21B
est: 20.10B (-14.4%)
|
30.91B
est: 21.25B (+45.5%)
|
14.68B
est: 22.03B (-33.4%)
|
18.26B
est: 24.56B (-25.7%)
|
20.72B
est: 24.53B (-15.5%)
|
23.96B
est: 24.97B (-4.1%)
|
25.03B
24.27B – 25.67B
+0.2% YoY
|
26.57B
25.77B – 28.13B
+6.1% YoY
|
28.28B
27.43B – 29.48B
+6.4% YoY
|
29.51B
28.62B – 30.76B
+4.3% YoY
|
30.77B
29.84B – 32.08B
+4.3% YoY
|
| EBIT |
4.91B
est: 4.48B (+9.6%)
|
5.89B
est: 5.54B (+6.4%)
|
5.98B
est: 5.14B (+16.4%)
|
6.67B
est: 6.80B (-1.9%)
|
7.16B
est: 7.28B (-1.7%)
|
8.26B
est: 7.85B (+5.3%)
|
7.72B
est: 8.60B (-10.2%)
|
9.79B
est: 6.96B (+40.6%)
|
10.47B
est: 9.53B (+9.9%)
|
12.39B
est: 11.41B (+8.6%)
|
11.31B
est: 13.35B (-15.3%)
|
11.96B
est: 10.61B (+12.7%)
|
11.49B
est: 11.76B (-2.3%)
|
12.98B
est: 10.91B (+18.9%)
|
8.79B
est: 9.61B (-8.5%)
|
8.52B
est: 8.56B (-0.4%)
|
9.85B
est: 8.38B (+17.6%)
|
15.03B
est: 9.24B (+62.6%)
|
9.79B
est: 13.02B (-24.8%)
|
10.75B
est: 9.45B (+13.7%)
|
25.32B
est: 10.00B (+153.2%)
|
7.98B
est: 10.36B (-23.0%)
|
9.98B
est: 17.21B (-42.0%)
|
14.65B
est: 16.01B (-8.5%)
|
18.38B
est: 17.50B (+5.0%)
|
17.54B
17.01B – 17.99B
+0.2% YoY
|
18.62B
18.06B – 19.71B
+6.1% YoY
|
19.82B
19.22B – 20.66B
+6.4% YoY
|
20.68B
20.05B – 21.55B
+4.3% YoY
|
21.56B
20.91B – 22.48B
+4.3% YoY
|
| Net Income |
3.84B
est: 4.10B (-6.4%)
|
4.73B
est: 5.35B (-11.6%)
|
4.74B
est: 4.76B (-0.4%)
|
5.37B
est: 5.86B (-8.4%)
|
6.13B
est: 6.49B (-5.5%)
|
7.18B
est: 7.01B (+2.3%)
|
11.95B
est: 7.77B (+53.8%)
|
8.20B
est: 12.26B (-33.2%)
|
8.40B
est: 8.71B (-3.6%)
|
9.79B
est: 9.60B (+2.0%)
|
8.94B
est: 11.34B (-21.2%)
|
9.27B
est: 8.79B (+5.4%)
|
9.18B
est: 9.71B (-5.5%)
|
10.21B
est: 9.19B (+11.1%)
|
17.78B
est: 8.85B (+101.0%)
|
6.71B
est: 17.21B (-61.0%)
|
7.70B
est: 6.80B (+13.4%)
|
12.61B
est: 8.18B (+54.1%)
|
11.73B
est: 11.57B (+1.4%)
|
8.07B
est: 12.21B (-33.9%)
|
24.02B
est: 12.91B (+86.1%)
|
6.96B
est: 13.38B (-48.0%)
|
14.85B
est: 11.25B (+32.0%)
|
11.94B
est: 14.86B (-19.6%)
|
14.65B
est: 16.89B (-13.3%)
|
18.04B
15.68B – 18.13B
+6.8% YoY
|
20.00B
17.19B – 20.48B
+10.9% YoY
|
22.39B
18.99B – 23.94B
+12.0% YoY
|
22.32B
21.45B – 23.56B
-0.3% YoY
|
24.09B
23.14B – 25.42B
+7.9% YoY
|
| SGA |
7.17B
est: 7.40B (-3.2%)
|
7.88B
est: 9.66B (-18.4%)
|
9.24B
est: 8.19B (+12.8%)
|
9.99B
est: 10.79B (-7.4%)
|
10.63B
est: 11.72B (-9.2%)
|
11.97B
est: 13.21B (-9.4%)
|
13.26B
est: 13.43B (-1.3%)
|
14.10B
est: 13.61B (+3.6%)
|
14.33B
est: 14.99B (-4.4%)
|
15.80B
est: 16.38B (-3.6%)
|
18.05B
est: 18.29B (-1.3%)
|
15.12B
est: 17.42B (-13.2%)
|
15.24B
est: 17.67B (-13.7%)
|
14.99B
est: 17.63B (-15.0%)
|
14.25B
est: 12.99B (+9.7%)
|
14.19B
est: 13.66B (+3.9%)
|
12.47B
est: 14.29B (-12.7%)
|
13.72B
est: 13.24B (+3.6%)
|
14.37B
est: 12.56B (+14.4%)
|
14.20B
est: 14.90B (-4.7%)
|
12.83B
est: 15.76B (-18.6%)
|
12.19B
est: 16.33B (-25.4%)
|
12.52B
est: 14.46B (-13.5%)
|
12.57B
est: 18.18B (-30.9%)
|
13.87B
est: 14.71B (-5.7%)
|
14.74B
14.29B – 15.12B
+0.2% YoY
|
15.65B
15.18B – 16.56B
+6.1% YoY
|
16.65B
16.15B – 17.36B
+6.4% YoY
|
17.38B
16.85B – 18.11B
+4.3% YoY
|
18.12B
17.58B – 18.89B
+4.3% YoY
|
| EPS |
1.49
est: 0.97 (+52.8%)
|
1.88
est: 1.38 (+35.9%)
|
1.99
est: 1.59 (+25.2%)
|
2.28
est: 2.21 (+3.3%)
|
2.63
est: 2.05 (+28.0%)
|
3.06
est: 2.57 (+19.0%)
|
5.15
est: 2.91 (+77.0%)
|
3.62
est: 3.41 (+6.0%)
|
3.70
est: 4.05 (-8.6%)
|
4.28
est: 5.56 (-23.1%)
|
3.75
est: 6.02 (-37.7%)
|
3.93
est: 5.57 (-29.4%)
|
3.76
est: 5.67 (-33.7%)
|
4.21
est: 5.70 (-26.1%)
|
7.40
est: 4.24 (+74.6%)
|
2.82
est: 3.88 (-27.3%)
|
3.28
est: 3.99 (-17.9%)
|
5.44
est: 4.39 (+24.0%)
|
3.12
est: 4.95 (-36.9%)
|
3.55
est: 5.49 (-35.4%)
|
10.71
est: 5.95 (+80.1%)
|
3.19
est: 5.70 (-44.0%)
|
7.11
est: 5.50 (+29.4%)
|
5.92
est: 7.54 (-21.5%)
|
7.56
est: 8.93 (-15.3%)
|
8.48
8.02 – 9.27
-5.0% YoY
|
9.46
8.79 – 10.48
+11.5% YoY
|
10.54
9.71 – 12.25
+11.4% YoY
|
11.42
10.97 – 12.05
+8.4% YoY
|
12.32
11.84 – 13.00
+7.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
No beneficial ownership filings recorded.
Institutional Activity (13F)
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | PARTNERS CAPITAL INVESTMENT GROUP, LLP | 31.3K -11.1K (-26.2%) | 4.32M -1.0M (-19.1%) | 0.00% -0.001 pp | 0.16% -0.052 pp | CHF97.84 +12.0% | 11 qtrs — |
| 2 | GENERALI INVESTMENTS CEE, INVESTICNI SPOLECNOST, A.S. | 18.1K +— (+0.0%) | 2.50M +227.6K (+10.0%) | 0.00% +0.000 pp | 0.18% +0.003 pp | CHF88.70 +23.6% | 5 qtrs — |
| 3 | BOSTON COMMON ASSET MANAGEMENT, LLC | — -129.0K (-100.0%) | — -16.2M (-100.0%) | 0.00% -0.007 pp | 0.00% -0.454 pp | CHF— | 12 qtrs SOLD |
| 4 | — | — -560.0 (-100.0%) | — -70.5K (-100.0%) | 0.00% +0.000 pp | 0.00% -0.013 pp | CHF— | 2 qtrs SOLD |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vasant Narasimhan | Chief Executive Officer | 8M | — |
| Victor Bulto | President of US | 3M | male |
| Mukul Mehta | Chief Financial Officer | 3M | male |
| Patrick Horber | President of International | 3M | — |
| Karen L. Hale | Chief Legal & Compliance Officer | 2M | female |
| Steffen Lang | President of Operations | 2M | male |
| Robert Kowalski | Chief People & Organization Officer | 2M | — |
| Sloan Simpson | Global Head of Investor Relations | — | female |
| Evan Beckman | Global Head of Translational Medicine at Novartis Institute for BioMedical Research | — | male |
| Paul Penepent | Head of Group Financial Reporting and Accounting | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NOVN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
